CSPG4 has been recognized as a potential target in cancer immunotherapy, as it is minimally expressed in healthy tissues, while being overexpressed in several cancers, including TNBC, the most aggressive breast cancer subtype majoritarily affecting patients of African descent (Hu et al. 2022; Hoffmann et al. 2020; Eng et al. 2018; Amoury et al. 2016a, b). The gene discussed is CSPG4; the disease is cancer.